Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: Cooperative effects with cis-platin and radiotherapy on patient-derived xenografts

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Gressette, Mélanie ^a   Vérillaud, Benjamin ^a   Jimenez Pailhès, Anne Sophie ^a   Lelièvre, Hélène ^b   Lo, Kwok Wai ^c   Ferrand, François Régis ^d   Gattolliat, Charles Henry ^a   Jacquet Bescond, Anne ^b   Kraus Berthier, Laurence ^b   Depil, Stéphane ^b   Busson, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d University of Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; CELL PROTEIN; CISPLATIN; RAD51 PROTEIN; RNA EBER 1; UNCLASSIFIED DRUG; VIRUS RNA; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; EPSTEIN-BARR VIRUS ENCODED RNA 1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CASE REPORT; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN MODIFICATION; ADOLESCENT; ADULT; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EPSTEIN BARR VIRUS; FEMALE; GENETICS; IC50; MALE; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MALE; MICE; NASOPHARYNGEAL NEOPLASMS; RAD51 RECOMBINASE; RNA, VIRAL; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897477829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091325     Document Type: Article

References (40)

1. Feng BJ (2013) Descriptive, environmental and genetic epidemiology of nasopharyngeal carcinoma. In: Bussson P, editor. Nasopharyngeal carcinoma: Keys for Translational Medicine and Biology. Austin/New-York: Landes/Springer. pp. 23-41.
2. Gourzones C, Busson P, Raab-Traub N (2013) Epstein-Barr Virus and the Pathogenesis of Nasopharyngeal Carcinomas. In: Busson P, editor. Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology. Austin/New-York: Landes/Springer. pp. 42-60.
3. Jin Y, Ye X, Shao L, Lin BC, He CX, et al. (2013) Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. European journal of cancer 49: 1619-1626.
4. Su SF, Han F, Zhao C, Huang Y, Chen CY, et al. (2011) Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chinese journal of cancer 30: 565-573.
5. Hui EP, Chan ATC (2013) The evolving role of systemic therapy in nasopharyngeal carcinoma: Current strategies and perspectives. In: Busson P, editor. Nasopharyngeal carcinoma: Keys for Translational Medicine and Biology. Austin and New-York: Landes and Springer. pp. 149-172.
6. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, et al. (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. International journal of radiation oncology, biology, physics 66: 981-991. (Pubitemid 44633504)
7. Hui EP, Chan AT, Pezzella F, Turley H, To KF, et al. (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 2595-2604.
8. Chua DT, Nicholls JM, Sham JS, Au GK (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. International journal of radiation oncology, biology, physics 59: 11-20. (Pubitemid 38501502)
9. Lim WT, Ng QS, Ivy P, Leong SS, Singh O, et al. (2011) A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 5481-5489.
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England journal of medicine 354: 567-578. (Pubitemid 43209104)
11. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, et al. (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23: 3568-3576.
12. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, et al. (2007) Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. International journal of cancer Journal international du cancer 121: 2095-2104.
13. Hui EP, Ma BB, King AD, Mo F, Chan SL, et al. (2011) Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 1280-1287.
14. Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, et al. (2012) Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. International journal of cancer Journal international du cancer 131: 1930-1940.
15. Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, et al. (2013) The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clinical cancer research: an official journal of the American Association for Cancer Research 19: 6520-6531.
16. Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, et al. (2013) Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell death & disease 4: e738.
17. Busson P, Ganem G, Flores P, Mugneret F, Clausse B, et al. (1988) Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 42: 599-606. (Pubitemid 18264074)
18. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, et al. (1999) Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer research 59: 924-930. (Pubitemid 29086750)
19. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, et al. (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
20. Chan SY, Choy KW, Tsao SW, Tao Q, Tang T, et al. (2008) Authentication of nasopharyngeal carcinoma tumor lines. International journal of cancer Journal international du cancer 122: 2169-2171.
21. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, et al. (2008) Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 10: 1183-1194.
22. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, et al. (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83: 121-126. (Pubitemid 29409487)
23. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, et al. (1999) Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 59: 924-930. (Pubitemid 29086750)
24. Weinrib L, Li JH, Donovan J, Huang D, Liu FF (2001) Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Cancer gene therapy 8: 352-360. (Pubitemid 32685642)
25. Cheng Y, Stanbridge EJ, Kong H, Bengtsson U, Lerman MI, et al. (2000) A functional investigation of tumor suppressor gene activities in a nasopharyngeal carcinoma cell line HONE1 using a monochromosome transfer approach. Genes, chromosomes & cancer 28: 82-91. (Pubitemid 30176766)
26. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, et al. (1992) Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66: 3768-3775.
27. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335.
28. Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227: 168-170.
29. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, et al. (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 104: 19482-19487.
30. Chen X, Wong P, Radany EH, Stark JM, Laulier C, et al. (2012) Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Molecular cancer research: MCR 10: 1052-1064.
31. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, et al. (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15: 57-66.
32. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, et al. (2010) The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 10: 558.
33. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, et al. (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. International journal of radiation oncology, biology, physics 64: 47-56. (Pubitemid 41831208)
34. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, et al. (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The lancet oncology 13: 163-171.
35. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, et al. (2012) Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell death and differentiation 19: 1317-1327.
36. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, et al. (2013) The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One 8: e79781.
37. Balluff B, Rauser S, Meding S, Elsner M, Schone C, et al. (2011) MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. The American journal of pathology 179: 2720-2729.
38. Takada K (2012) Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Seminars in cancer biology 22: 162-165.
39. Lee N, Pimienta G, Steitz JA (2012) AUF1/hnRNP D is a novel protein partner of the EBER1 noncoding RNA of Epstein-Barr virus. RNA 18: 2073-2082.
40. Toczyski DP, Matera AG, Ward DC, Steitz JA (1994) The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 91: 3463-3467. (Pubitemid 24130257)